An interventional study of Treatment and Evaluation for After Metabolic Surgery with Eating Disorders (TEAM-ED) Program in Bariatric Surgery Patients and Disordered Eating Behaviors, sponsored by Aaron Keshen. Recruiting at 1 site in Canada. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.
Sponsored by Aaron Keshen · Not applicable, Interventional, and Health services research
The goal of this interventional study is to evaluate the Treatment and Evaluation for After Metabolic Surgery with Eating Disorders (TEAM-ED) program, which combines streamlined access to screening, diagnostic assessment, and treatment with an interdisciplinary team approach to treatment planning, for managing disordered eating in adults who have recently had weight loss surgery in Nova Scotia. The main question it aims to answer is 'can an interdisciplinary program for identifying and managing disordered eating after weight loss surgery be implemented in Nova Scotia?
This study will determine the feasibility and impact of the TEAM-ED program by assessing the following objectives:
Participants will complete a disordered eating screening questionnaire online every 3 months after weight loss surgery until they reach 18-months post-surgery. Participants found to have disordered eating will be referred to the Nova Scotia Provincial Eating Disorder Service (NSEDPS) for standard disordered eating treatment (brief cognitive behavioral therapy [CBT-T]) plus treatment plan oversight by both weight loss surgery and eating disorder specialists. Standard outcome measures will be collected at baseline, during eating disorder treatment, post-treatment, and at follow-ups. Participants may also be asked to do a one-on-one research interview about their experiences with the program.
Aaron Keshen is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Behavioral: Treatment and Evaluation for After Metabolic Surgery with Eating Disorders (TEAM-ED) Program
A program that combines a) streamlined access to screening, diagnostic assessment, and treatment (brief cognitive behaviour therapy \[CBT-T\]), b) an interdisciplinary team approach to treatment planning, for managing disordered eating in patients post-weight loss surgery.
Screening Engagement Rate
Percentage of eligible patients (i.e., post-weight loss patients who are enrolled in the screening procedure) who complete the disordered eating screening measure (i.e., Loss of Control Over Eating Scale \[LOCES\]) at each timepoint (3-, 6-, 9-, 12-, 15-, and 18-month). To be calculated with the equation: \[Actual # of LOCES completed at a timepoint\] / \[Total # of eligible patients who could have completed LOCES at that timepoint\]
Time frame: From the post-weight loss surgery timepoint when a participant is first enrolled in the screening procedure (3-, 6-, 9-, 12-, 15-, or 18-months) until 18-months post-surgery or until they screen positive for disordered eating.
Screening Initiation Rate
Percentage of eligible patients (i.e., those who are 3- to 18-months post-weight loss surgery and receiving follow-up care at the study clinics) who initiate the screening procedure. This will be calculated using the equation: \[number of patients who fill out their initial screening questionnaire\] / \[number of patients registered for follow-up care post-weight loss surgery at the study clinics\]. \*Screening questionnaire is the Loss of Control Over Eating Scale (LOCES).
Time frame: From 3- to 18-months post-weight loss surgery.
Proportion of eligible patients who screen positive for loss of control eating.
Proportion of eligible patients (i.e., those enrolled in the screening procedure) who are identified via screening questionnaire as having loss of control eating. This will be calculated using the equation: \[number of patients who screen positive for loss of control eating\] / \[number of patients enrolled in screening procedure\]. \*Screening questionnaire is the Loss of Control Over Eating Scale (LOCES).
Time frame: From 3- to 18-months post-weight loss surgery.
Proportion of eligible patients who undergo a disordered eating diagnostic interview.
Proportion of eligible patients (i.e., those who screen positive for disordered eating) who complete a disordered eating diagnostic interview led by a clinician using the Eating Disorder Examination - Bariatric Surgery Version (EDE-BSV).
Time frame: From the post-weight loss surgery timepoint when a participant is first enrolled in the screening procedure (3-, 6-, 9-, 12-, 15-, or 18-months) until they screen positive for disordered eating.
Proportion of eligible patients who are diagnosed with disordered eating.
Proportion of eligible patients (i.e., those in the screening procedure who screen positive then attend a disordered eating diagnostic interview) who are diagnosed with disordered eating by the clinician conducting the interview based on the results of that assessment.
Time frame: From the post-weight loss surgery timepoint when a participant is first enrolled in the screening procedure (3-, 6-, 9-, 12-, 15-, or 18-months) until they screen positive for disordered eating.
Proportion of eligible patients who start disordered eating treatment.
Proportion of eligible patients (i.e., those diagnosed with disordered eating following diagnostic interview) who choose to start treatment for disordered eating.
Time frame: From the post-weight loss surgery timepoint when a participant is first enrolled in the screening procedure (3-, 6-, 9-, 12-, 15-, or 18-months) until they screen positive for disordered eating.
Change in disordered eating symptom frequency from baseline to post-treatment.
Patients in TEAM-ED treatment will complete the Eating Disorder Examination Questionnaire (EDE-Q) before and after the core sessions of brief cognitive behavior therapy (i.e., Week 10).
Time frame: From baseline to post-treatment (Week 10).
Change in disordered eating psychopathology severity from baseline to Week 4.
Patients in TEAM-ED treatment will complete the Eating Disorder Examination Questionnaire (EDE-Q) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. EDE-Q global scores range from 0-6, with higher scores indicating increased severity of eating disorder psychopathology.
Time frame: From baseline to Week 4.
Change in disordered eating psychopathology severity from baseline to post-treatment (Week 10).
Patients in TEAM-ED treatment will complete the Eating Disorder Examination Questionnaire (EDE-Q) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. EDE-Q global scores range from 0-6, with higher scores indicating increased severity of eating disorder psychopathology.
Time frame: From baseline to post-treatment (Week 10).
Change in disordered eating psychopathology severity from baseline to 1-month follow-up.
Patients in TEAM-ED treatment will complete the Eating Disorder Examination Questionnaire (EDE-Q) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. EDE-Q global scores range from 0-6, with higher scores indicating increased severity of eating disorder psychopathology.
Time frame: From baseline to 1-month follow-up (i.e., 1 month after Week 10).
Change in disordered eating psychopathology severity from baseline to 3-month follow-up.
Patients in TEAM-ED treatment will complete the Eating Disorder Examination Questionnaire (EDE-Q) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. EDE-Q global scores range from 0-6, with higher scores indicating increased severity of eating disorder psychopathology.
Time frame: From baseline to 3-month follow-up (i.e., 3 months after Week 10).
Change in anxiety symptom severity from baseline to Week 4.
Patients in TEAM-ED treatment will complete the Generalized Anxiety Disorder Scale (GAD-7) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. GAD-7 total scores range from 0 to 21, with higher scores indicating greater severity of generalized anxiety symptoms.
Time frame: From baseline to Week 4.
Change in anxiety symptom severity from baseline to post-treatment (Week 10).
Patients in TEAM-ED treatment will complete the Generalized Anxiety Disorder Scale (GAD-7) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. GAD-7 total scores range from 0 to 21, with higher scores indicating greater severity of generalized anxiety symptoms.
Time frame: From baseline to post-treatment (Week 10).
Change in anxiety symptom severity from baseline to 1-month follow-up.
Patients in TEAM-ED treatment will complete the Generalized Anxiety Disorder Scale (GAD-7) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. GAD-7 total scores range from 0 to 21, with higher scores indicating greater severity of generalized anxiety symptoms.
Time frame: From baseline to 1-month follow-up (i.e., 1 month after Week 10).
Change in anxiety symptom severity from baseline to 3-month follow-up.
Patients in TEAM-ED treatment will complete the Generalized Anxiety Disorder Scale (GAD-7) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. GAD-7 total scores range from 0 to 21, with higher scores indicating greater severity of generalized anxiety symptoms.
Time frame: From baseline to 3-month follow-up (i.e., 3 months after Week 10).
Change in depression symptom severity from baseline to Week 4.
Patients in TEAM-ED treatment will complete the Patient Health Questionnaire (PHQ-9) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. PHQ-9 total scores range from 0 to 27, with higher scores indicating greater severity of depressive symptoms.
Time frame: From baseline to Week 4.
Change in depression symptom severity from baseline to post-treatment (Week 10).
Patients in TEAM-ED treatment will complete the Patient Health Questionnaire (PHQ-9) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. PHQ-9 total scores range from 0 to 27, with higher scores indicating greater severity of depressive symptoms.
Time frame: From baseline to post-treatment (Week 10).
Change in depression symptom severity from baseline to 1-month follow-up.
Patients in TEAM-ED treatment will complete the Patient Health Questionnaire (PHQ-9) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. PHQ-9 total scores range from 0 to 27, with higher scores indicating greater severity of depressive symptoms.
Time frame: From baseline to 1-month follow-up (i.e., 1 month after Week 10).
Change in depression symptom severity from baseline to 3-month follow-up.
Patients in TEAM-ED treatment will complete the Patient Health Questionnaire (PHQ-9) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. PHQ-9 total scores range from 0 to 27, with higher scores indicating greater severity of depressive symptoms.
Time frame: From baseline to 3-month follow-up (i.e., 3 months after Week 10).
Change in psychosocial impairment from baseline to Week 4.
Patients in TEAM-ED treatment will complete the Clinical Impairment Assessment (CIA) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. CIA total scores range from 0 to 48, with higher scores indicating greater psychosocial impairment due to eating disorder symptoms.
Time frame: From baseline to Week 4.
Change in psychosocial impairment from baseline to post-treatment (Week 10).
Patients in TEAM-ED treatment will complete the Clinical Impairment Assessment (CIA) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. CIA total scores range from 0 to 48, higher scores indicating greater psychosocial impairment due to eating disorder symptoms.
Time frame: From baseline to post-treatment (Week 10).
Change in psychosocial impairment from baseline to 1-month follow-up.
Patients in TEAM-ED treatment will complete the Clinical Impairment Assessment (CIA) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. CIA total scores range from 0 to 48, higher scores indicating greater psychosocial impairment due to eating disorder symptoms.
Time frame: From baseline to 1-month follow-up (i.e., 1 month after Week 10).
Change in psychosocial impairment from baseline to 3-month follow-up.
Patients in TEAM-ED treatment will complete the Clinical Impairment Assessment (CIA) at baseline, Week 4, post-treatment (Week 10), 1-month follow-up, and 3-month follow-up. CIA total scores range from 0 to 48, higher scores indicating greater psychosocial impairment due to eating disorder symptoms.
Time frame: From baseline to 3-month follow-up (i.e., 3 months after Week 10).
Change in weight from baseline to Week 4.
Patient weight as measured with a standard scale.
Time frame: From baseline to Week 4.
Change in weight from baseline to post-treatment (Week 10).
Patient weight as measured with a standard scale.
Time frame: From baseline to post-treatment (Week 10).
Change in weight from baseline to 1-month follow-up.
Patient weight as measured with a standard scale.
Time frame: From baseline to 1-month follow-up (i.e., 1 month after Week 10).
Change in weight from baseline to 3-month follow-up.
Patient weight as measured with a standard scale.
Time frame: From baseline to 3-month follow-up (i.e., 3 months after Week 10).
Treatment Non-Response Rate
Percentage of eligible patients (i.e., those who start disordered eating treatment) who are deemed as not progressing in therapy as expected (per the CBT-T treatment manual, as determined by the clinician conducting their sessions). To be calculated with the equation: \[# of patients who start CBT-T\] / \[# of patients deemed 'non-responders' by their clinician.\]
Time frame: From baseline (Week 1) to post-treatment (Week 10).
Treatment Completion Rate
Percentage of eligible patients (i.e., those who start disordered eating treatment) who complete the core treatment (i.e., 10 weekly sessions) and that complete core treatment plus follow-ups (i.e., 1- and 3-month sessions). To be calculated with the equation: \[# of patients who start CBT-T\] / \[# of patients recorded as having completed their prescribed course of treatment by their clinician.\]
Time frame: From baseline to 3-month follow-up (i.e., 3 months after Week 10)
Program Dropout Rate
Percentage of eligible patients (i.e., those who initiate the screening procedure) who dropout of the TEAM-ED program.
Time frame: From recruitment initiation (Month 0) to recruitment end (Month 24).
Acceptability of the TEAM-ED program to clinicians.
Clinicians engaged in the TEAM-ED program will be asked to complete a survey online at \~12 and 18 months into the study (i.e., following the start of recruitment). The objectives of these groups is to: Evaluate the interdisciplinary approach; Identify barriers and facilitators; Assess the perceived effectiveness; and Refine and optimize the model.
Time frame: At 12 and 18 months.
Adjunctive Pharmacotherapy Initiation Rate
Percentage of eligible patients (i.e., those who start disordered eating treatment) who initiate pharmacotherapy for related symptoms during their course of treatment. \*This variable is observational - pharmacotherapy initiation is not being directed or controlled by the research protocol or research team.
Time frame: From baseline to 3-month follow-up.
Patient satisfaction with the TEAM-ED program.
Patients in TEAM-ED treatment will participate in a semi-structured, one-on-one interview with a trained research assistant. The objectives of the interviews are to assess overall patient satisfaction with the program including strengths and weaknesses, perceived effectiveness, and areas requiring refinement.
Time frame: At 3-month follow-up (i.e., 3 months after Week 10).
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Disordered Eating Behavior
Aaron Keshen